ArriVent BioPharma (AVBP) to Release Earnings on Wednesday

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect ArriVent BioPharma to post earnings of ($0.66) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Down 4.8 %

AVBP stock opened at $19.80 on Wednesday. The stock has a market cap of $674.23 million, a P/E ratio of -7.71 and a beta of 1.47. The stock's fifty day simple moving average is $19.69 and its two-hundred day simple moving average is $25.08. ArriVent BioPharma has a 1-year low of $15.47 and a 1-year high of $36.37.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. B. Riley initiated coverage on shares of ArriVent BioPharma in a research report on Thursday, March 20th. They set a "buy" rating and a $37.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $39.00 target price on shares of ArriVent BioPharma in a research report on Friday, March 7th. Finally, Guggenheim assumed coverage on shares of ArriVent BioPharma in a research note on Monday, March 10th. They set a "buy" rating and a $45.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $39.00.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.